|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FLT3 ITD MRD
Test Code12542
CPT Codes
81245<br>This test is not available for New York patient testing<br>Restricted Client Code
Preferred Specimen
3 mL peripheral blood collected in an EDTA (lavender-top) tube
Minimum Volume
1 mL whole blood • 0.25 mL bone marrow
Other Acceptable Specimens
1 mL bone marrow collected in an EDTA (lavender-top) tube • 1 ug of previously isolated DNA submitted in a sterile transport tube
Instructions
Prefer to receive blood or bone marrow refrigerated. Room temperature specimens will need to be shipped next day. Only send DNA under unusual circumstances.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Whole blood and bone marrow
Room temperature: 72 hours
Refrigerated: 7 days
Frozen: Unacceptable
Isolated DNA
Room temperature: Unacceptable
Refrigerated: 7 days
Frozen: 14 days
Room temperature: 72 hours
Refrigerated: 7 days
Frozen: Unacceptable
Isolated DNA
Room temperature: Unacceptable
Refrigerated: 7 days
Frozen: 14 days
Methodology
Polymerase Chain Reaction
FDA Status
This test was developed and its performance characteristics determined by the Laboratory for Personalized Molecular Medicine™. It has not been cleared or approved by the U.S. Food and Drug Administration. However, such approval is not required for clinical implementation, and test results have been shown to be clinically useful.
Setup Schedule
Set up Varies; Report available: 7-10 days
Reference Range
Not detected
Clinical Significance
To track and identify previously detected FLT3 ITD mutations in post-treatment follow-up samples, a multiplex master mix targeting the juxtamembrane domain of the FLT3 gene is used to amplify DNA extracted from a patient sample.
Next-generation sequencing of the PCR products is used to identify DNA sequences specific to previously identified mutations detected at diagnosis. Bioinformatics tools facilitate the detection of these specific sequences present at an allelic sensitivity level of 5 x 10-5.
• Stratifying risk for AML recurrence
• Monitor internal tandem duplications (ITD) mutations in the FLT3 gene and evaluate for disease recurrence